Skip to main content

GenMark to Offer $60M of Stock in Public Offering

NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market on Monday that it plans to begin a public offering of $60 million of its common stock.

The company has not yet priced the offering.

Net proceeds will go toward general corporate purposes, such as acceleration of its test menu; furthering the development of its NexGen platform, expected to launch in the second half of 2014; the expansion of its domestic commercial team and acceleration of its international expansion; building up its administration infrastructure; automation of its manufacturing infrastructure; and other working capital requirements.

JP Morgan is the sole book-running manager for the proposed offering. GenMark said it intends to grant the underwriters a 30-day option to purchase up to $9 million in additional shares.

The Carlsbad, Calif.-based molecular diagnostics company last week reported a 44 percent increase in revenues for its second quarter.

In March, it filed a shelf registration to offer from time to time up to $150 million of its stock and/or other securities. In June 2012, GenMark raised about $39.3 million in a public offering of its stock.

In Thursday morning trade on the Nasdaq, shares of GenMark were down 3 percent at $9.43.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.